SCHEMBL68989

SCHEMBL68989

CCOC(=O)CNC(=O)c1cc(-c2ccccc2)on1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.58
RAB9A P51151 7/20 0.56
SMN1; SMN2 Q16637 7/20 0.56
NPC1 O15118 5/20 0.56
KMT2A Q03164 4/20 0.56
FAAH O00519 2/20 0.56
LMNA P02545 2/20 0.56
MAPK1 P28482 1/20 0.56
POLB P06746 1/20 0.54
HDAC3 O15379 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
TP53 P04637 2/20 0.52
STAT3 P40763 1/20 0.52
STAT1 P42224 1/20 0.52
HPGD P15428 1/20 0.52
MAOA P21397 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17079168 0.88 HIF1A (0.62) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL23822828 0.86 HIF1A (0.67) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL68906 0.84 HIF1A (0.70) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL17788443 0.83 HIF1A (0.68) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL70300 0.81 HPGD (0.59) RAB9ASMN1; SMN2NPC1KMT2AFAAH
SCHEMBL12349834 0.80 TP53 (0.78) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL768649 0.80 ACR (0.63) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL17510986 0.79 HIF1A (0.75) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL17652545 0.79 HIF1A (0.67) HIF1ARAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL18619872 0.78 FAAH (0.60) HIF1ARAB9ASMN1; SMN2NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 HIF1A 1520/4885RAB9A 3858/4885SMN1; SMN2 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.